Renewed Hope For Mild Alzheimer’s Patients As NICE Process On Anti-Dementia Medicines Ruled Unfair, UK
May 15th 2008Drug InformationAlzheimer's / Dementia News XML/RSS Feed
Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, welcomed today’s landmark ruling by the Court of Appeal. The Court found that the process by which the National Institute for Health and Clinical Excellence (NICE) decided to restrict anti-dementia medicines for newly diagnosed patients with mild Alzheimer’s disease was procedurally unfair.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
